Security Snapshot

Revolution Medicines, Inc. - *W EXP 12/17/202 (RVMDW) Institutional Ownership

CUSIP: 76155X118

13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

22

Shares (Excl. Options)

8,698,230

Price

$0.94

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Type / Class
Equity / *W EXP 12/17/202
Symbol
RVMDW on Nasdaq
Price per share
$1.79
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
8,698,230
Total reported value
$8,150,297
% of total 13F portfolios
0%
Share change
+651,445
Value change
+$712,708
Number of holders
22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • RVMDW - Revolution Medicines, Inc. - *W EXP 12/17/202 is tracked under CUSIP 76155X118.
  • 22 institutions reported positions in Q4 2025.
  • Schedule 13D/13G significant owner rows are not currently available.

What Changed

  • Holder count moved from 22 to 1 between Q4 2025 and Q1 2026.
  • Reported value moved from $8,150,297 to $805,500.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 22 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 76155X118?
CUSIP 76155X118 identifies RVMDW - Revolution Medicines, Inc. - *W EXP 12/17/202 in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

As of 31 Dec 2025, 22 institutional investors reported holding 8,698,230 shares of Revolution Medicines, Inc. - *W EXP 12/17/202 (RVMDW).

Institutional Holders of Revolution Medicines, Inc. - *W EXP 12/17/202 (RVMDW) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 450,000 $805,500 -$12,795 $1.79 1
2025 Q4 8,698,230 $8,150,297 +$712,708 $0.94 22
2025 Q3 8,066,230 $2,455,615 +$3,514 $0.30 21
2025 Q2 8,041,860 $2,116,552 +$143,332 $0.26 21
2025 Q1 7,647,321 $298,455 -$13,607 $0.04 22
2024 Q4 7,607,269 $1,314,887 +$528,254 $0.18 20
2024 Q3 4,670,066 $654,653 -$223,218 $0.14 21
2024 Q2 4,415,864 $449,673 -$2,591 $0.10 14
2024 Q1 6,884,843 $1,210,097 +$360,139 $0.18 21
2023 Q4 4,907,148 $1,621,737 +$1,596,327 $0.33 19
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .